Eli Lilly and Company (LLY) Shares Bought by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 23.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,800 shares of the company’s stock after purchasing an additional 6,754 shares during the quarter. Salem Investment Counselors Inc.’s holdings in Eli Lilly and were worth $3,015,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in LLY. BlackRock Inc. lifted its holdings in shares of Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after acquiring an additional 59,978,664 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after acquiring an additional 2,181,701 shares during the last quarter. Winslow Capital Management LLC lifted its holdings in shares of Eli Lilly and by 79.7% in the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after acquiring an additional 1,719,538 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Eli Lilly and by 93.6% in the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Eli Lilly and by 30.3% in the 1st quarter. Alliancebernstein L.P. now owns 3,477,371 shares of the company’s stock worth $292,482,000 after acquiring an additional 808,186 shares during the last quarter. Hedge funds and other institutional investors own 75.77% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) traded up 1.69% on Friday, reaching $82.92. 3,961,293 shares of the company’s stock were exchanged. The company’s 50 day moving average is $80.99 and its 200-day moving average is $82.04. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock has a market cap of $87.48 billion, a price-to-earnings ratio of 35.88 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.86 earnings per share. On average, analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were paid a dividend of $0.52 per share. The ex-dividend date was Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.51%. Eli Lilly and’s dividend payout ratio is currently 90.04%.

LLY has been the subject of a number of recent research reports. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a report on Tuesday, May 16th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and issued a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a report on Thursday, July 13th. Finally, Citigroup Inc. restated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a report on Tuesday, July 4th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average price target of $88.07.

In other news, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the transaction, the insider now owns 14,041 shares in the company, valued at $1,134,231.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $83.05, for a total value of $17,855,750.00. Following the transaction, the insider now owns 124,475,804 shares in the company, valued at approximately $10,337,715,522.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 826,900 shares of company stock worth $68,610,132. Insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/09/10/eli-lilly-and-company-lly-shares-bought-by-salem-investment-counselors-inc.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply